Device Trial Radar · NCT05866419
Study of an Intrathecal Port and Catheter System for Subjects With Spinal Muscular Atrophy
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Nov 27, 2023
Primary completion
Apr 2028
Study completion Jul 2030
Sponsor
- Lead sponsor
- Alcyone Therapeutics, IncNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Biogen
- First posted
- May 19, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 3 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the clinical investigation is to demonstrate successful clinical use of the ThecaFlex DRx™ System in delivering nusinersen in subjects with spinal muscular atrophy (SMA). All enrolled subjects will undergo implantation of the investigational device (ThecaFlex DRx™ System) and will be followed for 12 months after receiving the implant. The 12-month data will be used to assess the primary endpoint support a Pre-Market Approval (PMA) application.
Conditions
- Spinal Muscular Atrophy
- Spine Deformity
- Scoliosis
Interventions
ThecaFlex DRx SystemDevice
The ThecaFlex DRx™ System consists of an implantable intrathecal catheter, and an implantable subcutaneous port, designed specifically to meet the implantation, Cerebrospinal Fluid (CSF) aspiration, and intrathecal delivery and dosing needs of patients (aged ≥ 3 years) requiring repeated/on-going intermittent chronic bolus intrathecal treatment for life threatening, debilitating Central Nervous System (CNS) disorders who are precluded from Lumbar Puncture (LP) due to complex spine conditions, or who are resistant to LP for therapy administration or CSF aspiration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The proportion of subjects with successful Implantation of the ThecaFlex DRx™ Port and CatheterTime frame: 12 Months
- The proportion of subjects with successful Intrathecal Therapy Infusion(s) through 12 monthsTime frame: 12 Months
Locations
23 sites in 5 countries. Site status is shown where the registry gives one.
Barrow Neurological Institute
Phoenix, Arizona · Recruiting
Children's Hospital Orange County
Orange, California · Recruiting
Stanford Medical Center
Palo Alto, California · Recruiting
20 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.